Well for a while, the bottom has been holding. I am adding more shares soon. Looking at our possible competitors, the generics are out of commission until late 2016, FDA automatic stay for 30 months, then patents should hold them back for years to come. Astrazeneca on the other hand may get an injunction/penalty or have to pay a license fee to market their drug. This will have to be worked out in the court house. The SPA agreement could be worked out between FDA/AMARIN/Courts.
So the risk is leaning on your side, I think!
One note I dont believe:
EPANOVA=VASCEPA
More like EPANOVA=LOVAZA=GENERIC LOVAZA
As the science addresses EPA as the true anti-inflammatory drug.
The others may fade away over time.
News 
Market Data 
Discover 
AI
